Abstract
Cathepsin B belongs to a family of cathepsins and plays an important role in normal physiological functions in the cell. However, overexpression of cathepsin B has been associated with different malignancies, and this has made it an attractive pharmacological target. The advent of CRISPR-Cas9 technology has allowed researchers to efficiently knock down genes with very less nonspecific activity compared to earlier methods. The protocol described below will enable investigators to develop cathepsin B knockdown stable cells and explains ways to study the knockdown.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Greembaum LM, Fruton JS (1957) Purification and properties of beef spleen cathepsin B. J Biol Chem 226(173):173–180
Gondi CS, Rao JS (2013) Cathepsin B as a cancer target. Expert Opin Ther Targets 17(3):281–291
Rempel SA, Rosenblum ML, Mikkelsen T et al (1994) Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54(23):6027–6031
Bian B, Mongrain S, Cagnol S et al (2016) Cathepsin B promotes colorectal tumorigenesis, cell invasion, and metastasis. Mol Carcinog 55(5):671–687
Ruan J, Zheng H, Rong X et al (2016) Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Mol Cancer 15:17
Gong F, Peng X, Luo C et al (2013) Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma. Mol Cancer 12:125
Towatari T, Nikawa T, Murata M et al (1991) Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo. FEBS Lett 280(23):311–315
Stern I, Schaschke N, Moroder L et al (2004) Crystal structure of NS-134 in complex with bovine cathepsin B: a two-headed epoxysuccinyl inhibitor extends along the entire active-site cleft. Biochem J 381(Pt 2):511–517
Mikhaylov G, Klimpel D, Schaschke N et al (2014) Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated cathepsin B inhibitor. Angew Chem Int Ed Engl 53(38):10077–10081
Yunis AA, Arimura GK, Russin DJ (1977) Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19(1):128–135
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)). Methods 25(4):402–408
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Gnanamony, M., Gondi, C.S. (2018). Targeting the Expression of Cathepsin B Using CRISPR/Cas9 System in Mammalian Cancer Cells. In: Cal, S., Obaya, A. (eds) Proteases and Cancer. Methods in Molecular Biology, vol 1731. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7595-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7595-2_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7594-5
Online ISBN: 978-1-4939-7595-2
eBook Packages: Springer Protocols